Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate

Clinical Cancer Research

Volumn 23, Issue 15, 2017, Pages 4242-4250

  Kato, Shumei ^a   Goodman, Aaron ^a   Walavalkar, Vighnesh ^b   Barkauskas, Donald A ^c   Sharabi, Andrew ^a,d   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; ONCOPROTEIN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; DISEASE COURSE; EFGR GENE; ENDOMETRIUM SARCOMA; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOMICS; GROWTH RATE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MDM2 GENE; MDM4 GENE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CTLA-4 ANTIGEN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; NUCLEAR PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE;

EID: 85026810566     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3133     Document Type: Article

References (29)

1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small cell lung cancer. N Engl J Med 2015;373:1627–39.
2. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50.
3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.
4. Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2016;14:203–220.
5. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
6. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847–56.
7. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819–29.
8. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541–3.
9. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23:1920–8.
10. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
11. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692–6.
12. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 2012;18:2922–9.
13. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023–31.
14. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852–5.
15. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82–93.
16. Mehta CR, Patel N, Senchaudhuri P. Exact stratified linear rank tests for ordered categorical and binary data. J Comput Graphical Stat 1992;1: 21–40.
17. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54: 774–81.
18. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–20.
19. Lahmar J, Facchinetti F, Koscielny S, Ferte C, Mezquita L, Bluthgen MV. Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC). J Clin Oncol 2016;34: abstr 9034.
20. Saada-Bouzid E, Defaucheux C, Karabajakian A, Palomar Coloma V, Servois V, Paoletti X. Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD-1/PD-L1 inhibitors. J Clin Oncol 2016;34:suppl; abstr 6072.
21. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83–96.
22. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209–18.
23. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:20059–63.
24. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013;123:4464–78.
25. Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin 2014;46:180–9.
26. Zhou JX, Lee CH, Qi CF, Wang H, Naghashfar Z, Abbasi S, et al. IFN regulatory factor 8 regulates MDM2 in germinal center B cells. J Immunol 2009;183:3188–94.
27. Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of MDM2/X-targeted therapies. Front Oncol 2016;6:7.
28. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355–63.
29. Tawbi HA-H, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028–a multicenter phase II study. ASCO Annual Meeting Proc 2016;2016:11006.